$599

Protagonist to Advance Obesity Asset; Syntis Raises $33M Series A

Two cardiometabolic-related news items have been observed: Protagonist Therapeutics announced its new triple agonist obesity asset (view press release); and Syntis Bio raised Series A funding (view article). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here